<DOC>
	<DOCNO>NCT02497378</DOCNO>
	<brief_summary>The purpose study evaluate tolerability safety JNJ-54767414 ( daratumumab ) Combination With Bortezomib Dexamethasone ( D-Vd ) Japanese participant relapse ( return medical problem ) refractory ( respond treatment ) multiple myeloma .</brief_summary>
	<brief_title>A Study JNJ-54767414 ( Daratumumab ) Combination With Bortezomib Dexamethasone ( D-Vd ) Japanese Participants With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>This open-label ( participant study personnel know identity study treatment ) multicenter ( study conduct multiple site ) study Japanese participant . The study include Screening Phase ( 21 day prior Cycle 1 Day 1 ) ; open-label treatment phase ( Cycle 1 Day 1 study treatment discontinuation , disease progression , unacceptable toxicity , reason ) , Follow-up Phase . Bortezomib Dexamethasone administer along JNJ-54767414 first 8 treatment cycle . Follow-up Phase begin immediately follow End-of-Treatment Visit , continue 8 week last study treatment , death , loss follow-up , consent withdrawal study participation , study end , whichever occur first . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants prove symptomatic ( symptom ) multiple myeloma ( MM ) accord International Myeloma Working Group ( IMWG ) diagnostic criterion Participant must document MM define follow criterion : Monoclonal plasma cell bone marrow 10 percent ( % ) , presence biopsyproven plasmacytoma point disease history , disease measurement : ) Serum Mprotein great equal ( &gt; = ) 1 gram per deciliter ( g/dL ) ( &gt; =10 gram per liter [ g/L ] ) b ) Serum immunoglobulin A [ IgA ] Mprotein &gt; = 0.5 g/dL ) ; c ) Urine Mprotein &gt; =200 milligram per 24 hour ( mg/24 h ) ; ) Serum immunoglobulin free light chain &gt; =10 mg/dL abnormal serum immunoglobulin kappa lambda free light chain ratio Participant must receive least 1 prior line therapy MM Participant must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Participant must achieve response ( partial response [ PR ] well base investigator 's determination response IMWG criterion ) least 1 prior regimen Participant receive daratumumab anticluster differentiation 38 ( antiCD38 ) therapies previously Is refractory bortezomib another PI , like ixazomib carfilzomib ( progression disease receive bortezomib therapy within 60 day end bortezomib therapy another PI therapy , like ixazomib carfilzomib Is intolerant bortezomib ( ie , discontinue due adverse event bortezomib treatment ) Has receive antimyeloma treatment within 2 week 5 pharmacokinetic halflives treatment , whichever longer , date daratumumab first administration . The exception emergency use short course corticosteroid ( equivalent dexamethasone 40 milligram per day [ mg/day ] maximum 4 day ) treatment . A list antimyeloma treatment correspond pharmacokinetic halflives provide Site Investigational Product Procedures Manual ( IPPM ) Has history malignancy ( multiple myeloma ) within 3 year date daratumumab first administration Has concurrent medical condition disease ( eg , active systemic infection , pulmonary impairment ) likely interfere study procedure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Daratumumab</keyword>
	<keyword>JNJ-54767414</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
</DOC>